A Retrospective Cohort Analysis of Transarterial Chemoembolization for Hepatocellular Cancer at a Tertiary Center in Switzerland
Open Access
- 2 June 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (11) , 3279
Abstract
Background/Objectives: International guidelines recommend transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (HCC). However, it is used outside these recommendations and has proven beneficial in prolonging survival. Since the role of TACE outside BCLC stage B is unclear, the present study analyzed the results of TACE performed at a tertiary center in Switzerland for different treatment groups, and aims to highlight the treatment outcomes for these groups. Methods: This retrospective cohort study includes 101 HCC patients undergoing TACE at our center. Patients were further subdivided into groups according to therapy combinations (therapies applied before and after index TACE). Kaplan–Meier survival curves were calculated for the Barcelona Center for Liver Cancer (BCLC) subgroups. Results: After TACE, the median survival was 28.1 months for BCLC 0, 31.5 months for BCLC A, 20.5 months for BCLC B, 10.8 for BCLC C, and 7.5 months for BCLC D. A lesion size larger than 55 mm was negatively associated with survival (HR 2.8, 95% CI 1.15–6.78). Complications occurred after TACE procedures: Clavien–Dindo I + II = 30, Clavien–Dindo > 3 = 2. Conclusions: TACE was performed in a substantial part of our cohort outside of routinely used treatment guidelines. The combination of the survival data and complication rate in these patients suggests it was a safe and beneficial strategy. Furthermore, our data show that in our cohort, the survival benefit associated with TACE was restricted to patients with a lesion size smaller than 55 mm.Keywords
This publication has 50 references indexed in Scilit:
- Epidemiology of Hepatocellular CarcinomaHepatology, 2020
- SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study)Journal of Gastrointestinal Cancer, 2020
- International trends in hepatocellular carcinoma incidence, 1978–2012International Journal of Cancer, 2019
- Projections of primary liver cancer to 2030 in 30 countries worldwideHepatology, 2017
- AASLD guidelines for the treatment of hepatocellular carcinomaHepatology, 2017
- Operative Microwave Ablation for Hepatocellular Carcinoma: Complications, Recurrence, and Long-Term OutcomesJournal of Gastrointestinal Surgery, 2013
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinomaLiver Transplantation, 2004
- A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolizationCancer, 2000
- The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstructionCancer, 1997